Skip to content

Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation

Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00670904
Enrollment
101
Registered
2008-05-02
Start date
2005-10-31
Completion date
2007-11-30
Last updated
2010-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking, Tobacco Use Disorder

Keywords

Smoking cessation, Pharmacist-delivered

Brief summary

This randomized trial compared the effectiveness of a three session pharmacist-delivered group program for smoking versus one 5 to 10 minute standard care session delivered over the telephone on 7-day point prevalence quit rates. Participants in both groups were offered their choice of bupropion IR or nicotine patch at no cost. At 6 months after the established quit date, self-reported cessation was biochemically verified using tests for urinary cotinine.

Interventions

OTHERPharmacist-delivered group program for smoking cessation

Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.

OTHERBrief standard care session for smoking cessation delivered over the telephone

Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.

Sponsors

Prevent Cancer Foundation
CollaboratorOTHER
University of Montana
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Smoked one or more cigarettes daily for 7 days * Somewhat ready to quit in the next 2 weeks (4 or more on a 10- point scale) * Willing and capable of attending three scheduled sessions at the clinic * Interested in participating in the study

Exclusion criteria

* Planned to leave the area in the next 6 months * Used pharmacotherapy for smoking cessation in the last 30 days * Used other forms of tobacco in the last 30 days * Schizophrenia * Prior participation

Design outcomes

Primary

MeasureTime frame
The primary outcome variable for the study was biochemically verified 7-day point prevalence smoking cessation at 6 months, defined as having smoked no cigarettes - not even a puff - for the previous 7 days.6 months

Secondary

MeasureTime frame
Secondary outcomes included 30-day point prevalence abstinence and prolonged abstinence (>6 months).6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026